Compounds > 2,3-bis(3'-hydroxybenzyl)butyrolactone
Page last updated: 2024-09-02

2,3-bis(3'-hydroxybenzyl)butyrolactone and Myocardial Infarction

2,3-bis(3'-hydroxybenzyl)butyrolactone has been researched along with Myocardial Infarction in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arts, IC; Boer, JM; Bueno-de-Mesquita, HB; Hollman, PC; Kok, FJ; Kuijsten, A; van't Veer, P1

Other Studies

1 other study(ies) available for 2,3-bis(3'-hydroxybenzyl)butyrolactone and Myocardial Infarction

ArticleYear
Plasma enterolignans are not associated with nonfatal myocardial infarction risk.
    Atherosclerosis, 2009, Volume: 203, Issue:1

    Topics: 4-Butyrolactone; Adult; Antioxidants; Cardiovascular Diseases; Case-Control Studies; Female; Humans; Lignans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk; Treatment Outcome

2009